Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J submits PMA for personalized sedation

This article was originally published in The Gray Sheet

Executive Summary

Ethicon Endo-Surgery unit of Johnson & Johnson submits PMA application to FDA for its Sedasys computer-assisted personalized sedation system. The device is intended for use by physician/nurse teams to administer minimal to moderate doses of propofol to sedate patients undergoing colonoscopies for the diagnosis and screening of colorectal cancer, as well as upper gastrointestinal disorders. The PMA is supported by a 1,000-patient, U.S. trial randomizing Sedasys to the current standard of care, which consists of physician-administered benzodiazepine and opioids

You may also be interested in...

DePuy Orthopaedics Counting On Knee Pipeline To Regain Market Lead

Johnson & Johnson/DePuy Orthopaedics expects to regain the lead in the knee repair market with a series of new device launches planned for the next few years, executives said during a day-long meeting with Wall Street analysts June 5

HLB Takes First Expansion Step Via Immunomic Acquisition

South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.

QUOTED. 20 February 2020. Steven Raman.

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts